A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin by Elizabeth D. Hermsen et al.
RESEARCH ARTICLE Open Access
A retrospective study of outcomes of
device-associated osteomyelitis treated
with daptomycin
Elizabeth D. Hermsen1,2, Luke Mendez-Vigo1, Elie F. Berbari3, Thomas Chung1, Minjung Yoon1
and Kenneth C. Lamp1*
Abstract
Background: Daptomycin appears well tolerated and effective for osteomyelitis treatment. However, limited data
exist regarding daptomycin use for treatment of device-associated osteomyelitis (DAO).
Methods: We used a retrospective, observational database (Cubicin® Outcomes Registry and Experience [CORE®
2007–2009]) that assessed patients treated with daptomycin to evaluate the characteristics of patients with DAO,
outcomes after daptomycin treatment, and safety of daptomycin in this setting. Information from 54 institutions
for patients with prosthetic joint infection (PJI) and other hardware-associated osteomyelitis (OHAO) who received
daptomycin from January 2007 to December 2008 with follow-up data in 2009 was collected using a standardized data
collection form.
Results: Eighty-two patients receiving daptomycin were identified in CORE 2007–2009; 48 patients (59 %) had follow-up
data. Sixty-seven percent of patients had received a previous antibiotic. Surgical intervention was similar between the 2
groups: PJI, 22 of 27 (82 %) and OHAO, 17 of 21 (81 %). However, device removal or replacement was more frequent in
the PJI patients (17 of 27, 63 %) than in the OHAO patients (8 of 21, 38 %). Clinical success was reported in 22 of 27
(82 %; 95 % confidence interval [CI], 62–94 %) patients with PJI and 18 of 21 (86 %; 95 % CI, 64–97 %) patients
with OHAO at follow-up (13–402 days). Adverse events occurred in 8 of 50 (16 %) patients in the safety population and
did not differ by daptomycin dose.
Conclusion: Daptomycin appeared effective and well tolerated in patients with DAO, including PJI or OHAO.
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Background
Daptomycin is a cyclic lipopeptide with potent activity
against a broad range of Gram-positive organisms [1–3].
Daptomycin is approved for the treatment of compli-
cated skin and skin structure infections due to cer-
tain Gram-positive bacteria and for the treatment of
Staphylococcus aureus bacteraemia and right-sided in-
fective endocarditis [4].
Device-associated osteomyelitis (DAO), such as pros-
thetic joint infection (PJI), is an increasing and costly
problem associated with high morbidity rate and pro-
longed hospitalization [5]. Rates of PJI have been reported
to be 0.5–1.0 % after hip replacement and 1–2 % after
knee replacement surgery [6]; these procedures are per-
formed annually in 12.0 and 27.9 per 10,000 adults age
45–64 years, respectively, and 33.0 and 83.4 per 10,000
adults age 65 years and older, respectively (based on
2007 U.S. hospital discharges) [7]. While many organ-
isms can cause PJI, methicillin-susceptible S. aureus
(MSSA), methicillin-resistant S. aureus (MRSA), and
coagulase-negative staphylococci (CoNS) are the most
frequently reported [8, 9].
Current data suggest that daptomycin appears to be an
effective and well-tolerated treatment option in patients
with osteomyelitis [10–13]. However, limited data are
available describing the clinical experience of daptomy-
cin specific to DAO [5, 8, 13, 14].
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The purpose of this study was to describe the charac-
teristics and management of patients with DAO treated
with daptomycin, including those with PJI and other
hardware-associated osteomyelitis (OHAO), and to as-
sess clinical outcomes and safety using retrospective data
collected in an observational database.
Methods
This study was performed at multiple institutions of in-
vestigators involved in the Cubicin® Outcomes Registry
and Experience (CORE® 2007–2009) program. CORE
was a retrospective observational database designed to
assess the demographic characteristics and clinical out-
come of patients treated with daptomycin. After institu-
tional review board (IRB) approval from the Chesapeake
IRB (CRRI 0504020) with a waiver of informed consent
and at each participating site requiring local approval, 54
institutions in the United States collected information
using a standardized data collection form from January
2007 to December 2008. Data from patients treated with
daptomycin included age; sex; weight; renal function;
type of dialysis (if applicable); comorbidities; daptomycin
initial and final dose, dosing interval, and length of ther-
apy; prior, concomitant, and follow-up antibiotic therapy;
infection details; outcomes; discharge information; and
safety assessments. Detailed CORE methodology has
been previously published by Rolston et al [15].
Patients
The study population included patients from CORE
with DAO (PJI and OHAO). Patients were included if
they were diagnosed with osteomyelitis in the presence
of prosthetic device/hardware, completed therapy with
daptomycin, and had a documented follow-up assess-
ment in 2009. A total of 82 patients were identified as
having DAO and successfully completing daptomycin
therapy in CORE 2007–2008.
Clinical outcome
Patient clinical outcome was categorized as cure, im-
proved, failure, or non-evaluable. Clinical cure was defined
as at least 1 of the following: clinical signs and symptoms
resolved; no additional antibiotic therapy necessary; and/
or negative culture reported at the end of therapy. An im-
proved clinical outcome was defined as partial resolution
of clinical signs and symptoms and/or additional antibiotic
therapy warranted at the end of therapy. Clinical failure
was defined as any of the following: inadequate response
to therapy (worsening or new/recurrent signs and symp-
toms), a required change in antibiotic therapy, or positive
culture reported at the end of therapy. Clinical outcome
was considered non-evaluable if the information was in-
sufficient to determine response. Clinical success was de-
fined as the sum of patients with clinical cure and those
who had improved clinical outcome. Outcome was deter-
mined at the last follow-up assessment after daptomycin
therapy was completed.
Data analysis
Data analysis was conducted using SAS 9.1 (SAS Institute,
Inc., Cary, North Carolina). The efficacy analysis included
patients with evaluable follow-up data in CORE 2009. The
safety analysis included all treated patients with DAO
who completed therapy with daptomycin and had a
documented follow-up assessment in CORE 2009, in-
cluding those non-evaluable for clinical outcome. The
Fisher’s exact test and a Kaplan-Meier analysis were used
to determine statistical significance, which was defined as
a p value < 0.05; an exact 95 % confidence interval (CI)
was also calculated.
Results
Patient demographics and characteristics
Of the 82 identified patients with DAO who successfully
completed therapy with daptomycin, 32 (39 %) were
from institutions that did not participate in CORE 2009
and had no follow-up information, while 48 (59 %) had
follow-up information in CORE 2009 and were evalu-
able. Two additional patients were non-evaluable and
were only included in the safety analysis. In the evalu-
able population, PJI was diagnosed in 56 % (27 of 48)
and OHAO in 44 % (21 of 48) (Table 1). The most com-
mon pathogen identified was MRSA in 27 % (13 of 48)
of patients (Table 2).
Daptomycin dosage regimen
The median (range) initial daptomycin dose in all evalu-
able patients was 6 (4.0–9.0) mg/kg (Table 1). The median
(range) duration of daptomycin therapy was 41 (6–70)
days (Table 1). A dose of ≥ 6 mg/kg was received by 22 of
27 (81 %) and 16 of 21 (76 %) evaluable patients with PJI
and OHAO, respectively. Six patients (4 [15 %] PJI; 2
[10 %] OHAO) received a daptomycin dose of ≥ 8 mg/kg.
Prior antibiotic therapy
Previous antibiotic use, including multiple antibiotic reg-
imens, occurred in most patients (PJI, 18 of 27 [67 %];
OHAO, 14 of 21 [67 %]). Vancomycin, the most com-
mon prior antibiotic, was administered in 37 % (10 of
27) and 43 % (9 of 21) of PJI and OHAO patients, re-
spectively. The median (range) duration of previous anti-
biotic therapy was 10 (1–90) days in patients with PJI
and 10 (2–26) days in patients with OHAO. The most
common reason for switching to daptomycin among
evaluable patients was a narrowed spectrum in 8 of 18
(44 %) PJI and 7 of 14 (50 %) OHAO patients.
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Surgery
The percentage of patients who received surgical interven-
tion was similar between the two groups: approximately
82 % for PJI, and 81 % for OHAO (Table 1). However,
device removal or replacement was more frequent in the
PJI patients (17 of 27 [63 %]) than in the OHAO patients
(8 of 21 [38 %]).
Outcomes
Clinical success was reported in 22 of 27 (82 %; 95 % CI,
62–94 %) patients with PJI and 18 of 21 (86 %; 95 % CI,
64–97 %) patients with OHAO at follow-up, ranging
from 13 to 402 days after therapy. Failures were reported
in two patients within 30 days, one within 30 to 60 days,
two within 61 to 180 days, and three after more than
180 days of follow-up. Kaplan-Meier analyses stratified by
dose of < 6 mg/kg, 6 to < 8 mg/kg, and ≥ 8 mg/kg showed
an overall difference (p = 0.001) in the median time to fail-
ure (not shown). Although the longest time to failure was
observed in those receiving daptomycin 6 to <8 mg/kg, the
clinical significance should be interpreted cautiously due to
small sample sizes for the < 6 mg/kg (n = 10) and ≥ 8 mg/kg
(n = 6) groups. Kaplan-Meier analysis did not show a differ-
ence in outcomes by device type. Success was reported in
77 % (10 of 13) of patients with MRSA, 43 % (3 of 7) of
those with MSSA, and 100 % (9 of 9) of those with CoNS.
Surgical removal or replacement for either device tended to
show better success rates; PJI: 8 of 8 (100 %) vs. 10 of 13
(77 %), p = 0.3; and OHAO: 15 of 17 (88 %) vs. 7 of 10
(70 %), p = 0.3.
Safety
No deaths or serious adverse events (AEs) were reported.
Twelve AEs occurred in 8 of 50 (16 %) patients in the
safety population and did not differ by daptomycin dose;
Table 1 Demographic characteristics of patients with device-associated osteomyelitis treated with daptomycin in the CORE
database
Characteristic No follow-up in CORE 2009 Evaluable population
PJI OHAO
(n = 32) (n = 27)a (n = 21)a
Sex, n (%)
Female 18 (56.3) 12 (44.4) 12 (57.1)
Male 14 (43.8) 15 (55.6) 9 (42.9)
Median weight, kg (range) 81.4 (37.1–120.0) 86.4 (44.1–128.9) 79.0 (40.0–136.4)
Age group (y), n (%)
≤ 50 6 (18.8) 4 (14.8) 13 (61.9)
51–65 14 (43.8) 12 (44.4) 7 (33.3)
≥ 66 12 (37.5) 11 (40.7) 1 (4.8)
In community 48 h prior to receiving daptomycin, n (%) 15 (46.9) 13 (48.1) 11 (52.4)
ICU stay during daptomycin, n (%) 7 (21.9) 1 (3.7) 0 (0.0)
Initial creatinine clearance 5 (15.6) 2 (7.4) 0 (0.0)
< 30 mL/min, n (%)
Surgical intervention, n (%) 22 (68.8) 22 (81.5) 17 (81.0)
At least 1 pathogen identified, n (%) 22 (68.8) 20 (74.1) 18 (85.7)
Median initial daptomycin dose, mg/kg (range) 6 (4–13.5) 6 (4–9) 6 (4–8)
Median duration of daptomycin, days (range) 35 (2–78) 41 (6–70) 40 (8–62)
CORE Cubicin® Outcomes Registry and Experience, ICU intensive care unit, OHAO other hardware-associated osteomyelitis, PJI prosthetic joint infection
aOne patient in each of the PJI and OHAO groups was not included in the evaluable population
Table 2 Microbiology of patients with device-associated osteo-
myelitis treated with daptomycin in the CORE database




(n = 32) (n = 27) (n = 21)
Staphylococcus aureus (MRSA) 9 (28.1) 6 (22.2) 7 (33.3)
Staphylococcus aureus (MSSA) 2 (6.3) 3 (11.1) 4 (19.0)
Other Staphylococcus aureusb 1 (3.1) 1 (3.7) 0 (0.0)
Coagulase-negative staphylococci 3 (9.4) 6 (22.2) 3 (14.3)
Enterococcus spp. 4 (12.5) 3 (11.1) 3 (14.3)
Vancomycin-resistant enterococci 1 (3.1) 1 (3.7) 2 (9.5)
Streptococcus spp. 0 (0.0) 0 (0.0) 1 (4.8)
Other 7 (21.9) 3 (11.1) 1 (4.8)
CORE Cubicin® Outcomes Registry and Experience, MRSA methicillin-resistant
S. aureus, MSSA methicillin-susceptible S. aureus, OHAO other hardware-
associated osteomyelitis, PJI prosthetic joint infection
aPatients may have had more than one pathogen
bOther S. aureus includes methicillin susceptibility unknown
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all AEs were mild. The most common AE was increased
creatine phosphokinase (CPK) in 6 patients. Ten AEs were
considered possibly treatment related including all CPK
AEs. Daptomycin therapy was discontinued in three pa-
tients because of AEs (increased CPK, increased CPK with
myalgia, and increased alanine aminotransferase and as-
partate aminotransferase). Daptomycin was also temporar-
ily discontinued in one patient because of increased CPK.
Discussion
Daptomycin is a potent antibiotic with activity against
many Gram-positive organisms. Previous studies have
demonstrated the efficacy and safety of daptomycin in the
treatment of osteomyelitis [10–13, 16]. However, data on
the use of daptomycin in DAO are limited [5, 14]. In this
report, the clinical success observed in 83 % of all evaluable
patients is consistent with those of previously published re-
sults. Similar results were reported for osteomyelitis and
orthopedic device infections in a European CORE analysis
where clinical success at follow-up was 86 % [17]. Patients
who received daptomycin at a dose of 6 to < 8 mg/kg had a
better outcome than patients receiving doses < 6 mg/kg
or ≥ 8 mg/kg, although sample sizes in the latter two
groups were small.
The present analysis has several limitations. DAO is
relatively rare, with reported rates of 0.5–1.0 % after
hip replacement and 1–2 % after knee replacement sur-
gery [6], resulting in a limited pool of potential patients
for analysis. Furthermore, because data were collected
retrospectively from chart documentation, the number
of patients with follow-up data in 2009 was only slightly
more than half of those with available records. Follow-
up duration was uncontrolled and limited. In addition,
data were collected during daptomycin for surgery but
were not collected during follow-up. The presence of
Gram-negative pathogens might have been under-
reported; therefore, the results should be interpreted in
the context of these limitations.
Daptomycin is a concentration-dependent antibiotic.
Several in-vitro and animal model studies have shown
that high dose daptomycin results in enhanced killing
and a lower rate of emergence of resistance compared to
standard dosing [18]. Clinical studies have followed
demonstrating that high-dose daptomycin is generally
well-tolerated and results in good clinical response in
difficult to treat infections due to S. aureus or entero-
cocci [18, 19]. Although the current study had a small
number of patients receiving higher doses, more recent
studies in bone and joint infections are reporting on the
outcomes with high-dose daptomycin [20].
As noted earlier, data on daptomycin in DAO are lim-
ited. A previous small, randomized, controlled trial that
evaluated the safety and efficacy of daptomycin versus
standard-of-care therapy (vancomycin, teicoplanin, or
semisynthetic penicillin) in patients undergoing two-stage
revision arthroplasty for PJI demonstrated clinical success
in 14 of 24 (58.3 %) and 14 of 23 (60.9 %) patients in the
daptomycin 6- and 8-mg/kg groups, respectively, com-
pared with 8 of 21 (38.1 %) in the standard-of-care group
[8]. A retrospective review of 14 patients treated with
daptomycin for hip or knee PJI who were evaluable for ef-
ficacy reported an overall success rate of 79 % [9]. Further-
more, a retrospective analysis of osteomyelitis cases in the
European CORE database reported success rates with
daptomycin treatment in 71 % (41 of 58) of patients who
retained a permanent prosthetic device and 80 % (16 of
20) of patients who retained a temporary prosthetic device
[13]. A trend toward higher success rates for patients re-
ceiving daptomycin who have had their hardware removed
has been seen [13, 21]. A recent multicenter observational
retrospective study of retained PJI supports this trend.
Despite using a high dose of daptomycin, 10 mg/kg/d with
rifampin, for acute PJI due to fluoroquinolone-resistant
staphylococci, Lara-Tamayo et al. observed a 50 % failure
rate (9 of 18 patients) but did not detect an increase in
daptomycin minimum inhibitory concentration [14]. In
contrast, in this retrospective study, higher rates of clinical
success were reported (82 % of patients with PJI and 86 %
of patients with OHAO) at follow-up, ranging from 13 to
402 days after therapy.
Previous analyses have reported on the safety of dapto-
mycin in patients with osteomyelitis [10, 13, 22]. In the
current retrospective analysis, daptomycin also appeared
well tolerated. The most commonly reported AE was in-
creased CPK in 6 of 48 patients. This is consistent with
other clinical trials and database analyses of daptomycin
at doses ≥ 6 mg/kg in the treatment of osteomyelitis, in
which CPK elevations have been reported in 2.5–8.3 %
of patients [8, 22].
Guidelines for the diagnosis and management of PJI
published in 2013 by the Infectious Diseases Society of
America recommend daptomycin at 6 mg/kg as alter-
native treatment for PJI related to MSSA, MRSA, and
Enterococcus spp with a level of evidence of BIII (mod-
erate evidence, based on opinions of respected author-
ities, expert committee reports, clinical experience, or
descriptive studies) [23]. The present study supports
the recommended daptomycin dose of 6 mg/kg for the
treatment of PJI caused by these pathogens; however,
the level of evidence emphasizes the importance of
additional data.
Conclusions
Daptomycin appeared effective and well tolerated in
the treatment of patients with DAO, including PJI or
OHAO. Further studies are warranted to confirm
these findings.
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